A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy

Launched by M.D. ANDERSON CANCER CENTER · Oct 16, 2024

Keywords

ClinConnect Summary

This clinical trial is looking to understand how patients experience certain side effects, known as immune-related adverse events (irAEs), after receiving a type of cancer treatment called immune checkpoint inhibitor immunotherapy. Specifically, the study focuses on patients with conditions like inflammatory arthritis and polymyalgia rheumatica who have faced these side effects. By gathering detailed information, researchers hope to learn more about the severity and impact of these events on patients' lives.

To participate, individuals need to be at least 18 years old, able to speak some English, and have a diagnosis from a rheumatologist indicating they have experienced these side effects after their treatment. The study is currently recruiting participants of all genders. Those who join can expect to share their experiences in interviews, helping to provide valuable insights that may improve future patient care. It's important to note that individuals with severe cancer that is rapidly worsening or those with hearing issues that make it hard to participate in conversations will not be eligible for this study.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• The criteria are:
• • Patients aged 18 years and above
• • English (conversational level) speaking, with the ability to give informed consent
• • Patients with a rheumatologist clinician diagnosis of inflammatory arthritis irAE or PMR irAE following ICI therapy
• • Exclusion Criteria
• • Acutely life-threatening or worsening cancer
• • Hearing impairment functionally limiting participation in verbal interview